PULSE BIOSCIENCES INC

PLSENASDAQ

🏆 #1305 by market capEarnings Nov 3US Equity

$44.40▲ $3.09 (+6.96%)

Live

1h—

24h▲ 7.0%

7d▲ 17.2%

14d▲ 28.5%

30d▲ 71.5%

1y▲ 194.0%

🏦Market Cap

$3.07B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

-21.0%

Thin

💵FCF Margin

—

⚖️P/S Ratio

3940.8x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $43.91 – $45.11
52-Week Range: $12.56 – $45.90
Volume: $6.10B
Avg Volume: $6.92B
Shares Outstanding: 69.2M
Next Earnings: Oct 28, 2026

Fundamentals Snapshot

Annual Revenue: $350,000
Last Q Revenue: $434,000
P/E Ratio: —
P/S Ratio: 3940.8x
EPS (TTM): $-1.10
Dividend Yield: —

Why Investors Own PLSE

✓High-growth profile — revenue up +23.3% YoY with expanding US Equity exposure.
✓Healthy economics — 78% gross margin and 21% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$350,000▲ +25.1% YoY

Gross Margin (TTM)

77.8%▲ +0.1% YoY

Operating Income (TTM)

$70,700▲ +25.1% YoY

Free Cash Flow (TTM)

$73,500▲ +25.1% YoY

About PULSE BIOSCIENCES INC

Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.

🦦